Dynamk Capital

CellFE Inc. is a biotechnology company based in San Carlos, California, established in 2017. It specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. This innovative platform enhances the manufacturing and development of cell therapies by utilizing rapid cell compression techniques that facilitate the uptake of therapeutic molecules from surrounding fluids. By enabling the transport of hard-to-deliver molecules, CellFE aims to improve the effectiveness of treatments for various disorders, supporting medical researchers in their efforts to advance patient care and outcomes.

Lucid Scientific develops real-time cellular activity monitors for drug discovery and research. It serves academic institutions and pharmaceutical companies, offering innovative tools like RESIPHER for non-invasive, continuous measurement of oxygen consumption in cell cultures.

Vernal Biosciences specializes in producing high-purity messenger RNA (mRNA) for research and clinical applications. Its platform streamlines manufacturing processes, reducing uncertainty and development time in advanced therapeutics. Vernal offers flexible, high-quality mRNA supplies and services, allowing clients to conduct drug discovery and development without investing in dedicated teams or facilities.

Vernal Biosciences specializes in producing high-purity messenger RNA (mRNA) for research and clinical applications. Its platform streamlines manufacturing processes, reducing uncertainty and development time in advanced therapeutics. Vernal offers flexible, high-quality mRNA supplies and services, allowing clients to conduct drug discovery and development without investing in dedicated teams or facilities.

Bionter is a company focused on transforming analytical testing to enhance public health. It develops advanced analytical testing devices that provide critical particle testing services essential for ensuring patient safety. Bionter's sub-visible particle testing is a mandatory requirement for any parenteral preparation and is utilized in various applications, including stability testing, drug formulation, process development, and in-process control during manufacturing. Through innovative combination light obscuration technology and smart automation, Bionter enables its clients to improve the quality and safety of their products.

Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.

Virica Biotech is a biotechnology company focused on enhancing the development and production of viral vector therapeutic products to improve human health. The company has developed a proprietary Viral Sensitizer technology, which encompasses a library of over one hundred small molecules. These viral sensitizers are designed to safely bypass the natural immunological defenses present in both humans and animals, thereby facilitating more effective viral medicines. By employing a throughput screening process, Virica identifies these molecules to address unmet needs in the production processes of viral medicine producers, ultimately enabling them to enhance their offerings affordably and efficiently.

Envisagenics is a Huntington, New York-based company that develops a predictive analytics and bioinformatics platform to accelerate RNA therapeutics discovery. The cloud-based SpliceCore platform analyzes RNA sequencing data with artificial intelligence to identify splicing errors linked to disease, predict drug targets, and guide the design of RNA-based therapies. By translating transcriptomic insights into actionable targets, Envisagenics aims to reduce the time, cost, and risk of pharmaceutical development and to support partnerships with biopharma organizations. The firm focuses on uncovering RNA splicing alterations and translating them into therapeutic candidates, enabling researchers to validate targets and biomarkers more efficiently. The company originated as a spinout from Cold Spring Harbor Laboratory and emphasizes the use of AI and machine learning to simplify complex biomedical data for therapeutic discovery.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012, specializing in innovative technologies for cancer research and immunotherapy. The company has developed proprietary systems that capture, grow, and analyze cancer cells directly from patient blood samples, allowing for precise control over primary cell phenotype and function. This technology enhances the development and production of cell therapies, providing scientists with advanced tools for cell maintenance, expansion, and optimization. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to improve predictive therapy development and clinical outcomes for patients undergoing immunotherapy.

Vectron Biosolutions AS is a biotechnology company based in Trondheim, Norway, founded in 2008. It specializes in the development and marketing of vector technologies for the biotechnology and life science sectors. The company offers a range of products, including bacterial cloning vectors and expression vectors designed for recombinant protein production in bacteria. Vectron also provides customized vectors tailored for specific applications and produces recombinant proteins. In addition to its product offerings, the company delivers services in protein production, vector design, and molecular engineering, aimed at supporting clients in their life science research endeavors. Vectron's innovative technology employs an inducible promoter to enhance bacterial strains, resulting in improved yield and solubility of therapeutic proteins, thereby facilitating advancements in the field.

Alpenglow Biosciences offers an innovative end-to-end 3D pathology platform. It utilizes proprietary high-throughput light-sheet microscopes and cloud-based AI analysis software to nondestructively image large tissue samples in 3D at sub-cellular resolution, providing new insights for drug development and clinical diagnostics.

Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.

Lucid Scientific develops real-time cellular activity monitors for drug discovery and research. It serves academic institutions and pharmaceutical companies, offering innovative tools like RESIPHER for non-invasive, continuous measurement of oxygen consumption in cell cultures.

CellFE Inc. is a biotechnology company based in San Carlos, California, established in 2017. It specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. This innovative platform enhances the manufacturing and development of cell therapies by utilizing rapid cell compression techniques that facilitate the uptake of therapeutic molecules from surrounding fluids. By enabling the transport of hard-to-deliver molecules, CellFE aims to improve the effectiveness of treatments for various disorders, supporting medical researchers in their efforts to advance patient care and outcomes.

RoosterBio specializes in regenerative medicine, offering standardized human mesenchymal stromal cells for research and therapeutic applications. Its platform includes scalable bioprocessing tools, optimized media, and analytical services to streamline product development and accelerate clinical translation.

RoosterBio specializes in regenerative medicine, offering standardized human mesenchymal stromal cells for research and therapeutic applications. Its platform includes scalable bioprocessing tools, optimized media, and analytical services to streamline product development and accelerate clinical translation.

FloDesign Sonics is a company that specializes in innovative acoustic technology aimed at transforming the separations and filtration sectors. The firm utilizes 3D non-linear acoustic standing waves to capture, separate, and purify mixtures without the need for physical membranes, chemicals, or centrifugation. This groundbreaking approach has broad applications across various industries, including life sciences, oil and gas, food and beverage, and industrial processing. The primary focus of FloDesign Sonics is in bioprocess separations, where it applies its technology to enhance the manufacturing of life-saving biopharmaceuticals.

Envisagenics is a Huntington, New York-based company that develops a predictive analytics and bioinformatics platform to accelerate RNA therapeutics discovery. The cloud-based SpliceCore platform analyzes RNA sequencing data with artificial intelligence to identify splicing errors linked to disease, predict drug targets, and guide the design of RNA-based therapies. By translating transcriptomic insights into actionable targets, Envisagenics aims to reduce the time, cost, and risk of pharmaceutical development and to support partnerships with biopharma organizations. The firm focuses on uncovering RNA splicing alterations and translating them into therapeutic candidates, enabling researchers to validate targets and biomarkers more efficiently. The company originated as a spinout from Cold Spring Harbor Laboratory and emphasizes the use of AI and machine learning to simplify complex biomedical data for therapeutic discovery.

FloDesign Sonics is a company that specializes in innovative acoustic technology aimed at transforming the separations and filtration sectors. The firm utilizes 3D non-linear acoustic standing waves to capture, separate, and purify mixtures without the need for physical membranes, chemicals, or centrifugation. This groundbreaking approach has broad applications across various industries, including life sciences, oil and gas, food and beverage, and industrial processing. The primary focus of FloDesign Sonics is in bioprocess separations, where it applies its technology to enhance the manufacturing of life-saving biopharmaceuticals.